Day 2 :
Keynote Forum
Neelam Sherwani
Sultan Qaboos University, Oman
Keynote: Volatile isothiocyanates and bioactivity in Physorhynchus Chamaerapistrum
Time : 10:00-11:00
Biography:
Neelam Sherwani is consultant with Department of Biology, Sultan Qaboos University, Muscat , Oman. She Completed her PhD from Punjabi University, India. She has published 12 papers in reputed journals.
Abstract:
GC-MS, GC-FID, NMR and microplate antimicrobial assay were used to examine the composition and bioactivity of the volatiles from the leaves of Physorhynchus chamaerapistrum Bioss in order to understand the chemical basis for using the leaves to treat ear infection. About 94% of the volatiles was a mixture of C4-C8 isothiocyanates (1-7) and strong absorption bands at 994 and 924 cm-1, respectively, confirmed the presence of aliphatic isothiocyanates, from which 3-butenyl isothiocyanate (4) was isolated as a major product (89.2%) followed by butyl isothiocyanate (3) (3.5 %),ï€ ï¢-caryohyllene (2.3%) and ï¢-gurjunene (1.5%) respectively. The structures of 4 and 2-methyl-3-butenoic acid (8), obtained from alkaline hydrolysis of the oil, were inferred from IR, MS, 1D and 2D NMR data. The oil and compounds 4 and 8 inhibited the growth of Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus and Candida albicans at 313 ïg/ml and higher concentrations. This investigation lent support to the treatment of ear infection with volatiles from the leaves of P. chamaerapistrum and provides chemical evidence for classifying P. chamaerapistrum as an isothiocyanate chemotype and a Crucifer.
Break: Networking and Refreshments @ 11:00-11:30
- Pharmaceutical Sciences | Pharmaceutics | Novel Drug Delivery Systems | Pharmaceutical Technology | Pharmacy | Pharmacology and Toxicology | Pharmaceutical Care | Drug Discovery and Design | Clinical Pharmacy
Location: Dubai, UAE
Chair
Heyam Saad Ali
University of Khartoum, Sudan
Session Introduction
Rajender Reddy Leleti
Sambi Pharmaceuticals, India
Title: Innovative methods for synthesis of novel pharmacophores
Time : 11:30-12:00
Biography:
Rajender Reddy Leleti, CEO of Sambipharma, He has over 25+ years of scientific research experience in process development, process optimization, cost effective and safer route selection, synthesis of complex NCEs/APIs, total synthesis of biologically active molecules at Novartis Pharmaceuticals, Piramal Pharma Solutions, Sai Life Sciences, Harvard University, RWTH University and Scientifically trained by Nobel Laureates. He have published over 90 publications and patent. He is also a member of Ad-Hoc Board of Studies, Sardar Patel University, Gujarat and member of Scientific Advisory Council, Indrashil University, Gujarat.
Abstract:
In the modern drug discovery, several innovative models were introduced such as scaffold hopping, escape flatland, conformational restriction and chemical equivalents. It has gained a significant recognition in the scientific community. In this perspective, scientists are currently looking for novel attractive molecules for the synthesis and exploration in the drug discovery. The development of the new methodologies for key pharmacophore motifs will be accelerate the designing process of active APIs. In the recent years, we have designed and demonstrated several new asymmetric methodologies for following key pharmacophore motifs.
Heyam Saad Ali,
University of Khartoum, Sudan
Title: Targeted liposomes and theranostic applications in cancer treatment
Time : 12:00-12:30
Biography:
Prof. Dr. Heyam Saad Ali, M. Pharm., and Ph-D. currently joined University of Khartoum, faculty of pharmacy, Sudan Prof. contributed more than 70 articles to reputed international scientific journals and conferences, in different conventional, controlled and targeted drug delivery systems in pharmaceutical product development. She has been invited as speaker to numerous International conferences .Reviewer and member of editorial board of many international journals.
Abstract:
Traditional chemotherapy is not recommended in the clinical settings due the severe complications patients exercising during use. Some of these complications include: severe systemic problems, [MDR] and toxicity. The reasons of such off-targeted side effects are due to the poor specificity and selectivity of drug deliver systems to target the biological molecule in the site of cancerous tissue. Therefore, advancement in the targeted delivery systems using nanotechnology techniques and Nano carriers are the area of interest and attention of many researchers, scientists and academia’s. Currently, significant developments, approaches and strategies are utilized to target the cancerous tissue. From these strategies of targeting the drug delivery is using Nano carriers such as liposomes, polymer nanoparticles, dendrimers etc. In addition to strengthen the conjugation to the selected extracellular and intracellular biological molecules such as receptors, carbohydrate determinant antigen, antibodies etc. Further more, utilizing the biological microenvironment surrounding the cancerous tumor, such as in passive targeting, and PEGylated liposomes to overcome the biological barriers through its journey to the cancerous tissue or cells. Moreover, the Nano carrier can be functionalized with directed ligands [active targeting] and physical responsive stimuli using the relevant techniques for a particular application. This presentation will high lights various current and recent strategies to overcome the limitation of conventional chemotherapy. However, nanotechnology is still in infancy since a lot of toxicity of the used nanomaterials and ethical issues have not been resolved yet. cell receptors via surface-attached ligands that direct drug uptake into tumor cells or tumor-associated stromal cells, and so can increase the selectivity of drug delivery.
Break: Lunch @ 12:30-13:30
A Alper Ozturk,
Anadolu University, Turkey
Title: Current medical nanotechnology approaches in chronic pain treatment
Time : 13:30-14:00
Biography:
A Alper Öztürk has completed his PhD from Anadolu University, Department of Pharmaceutical Technology in 2017. He has published more than 10 research articles about new drug delivery system and nanocarrier systems.
Abstract:
Nanotechnology is a frequently used approach to problem solving in disease treatment and it can be considered as a collection of tools and ideas that can be applied in the pharmaceutical technology. Chronic pain (CP) is generally known as any type of pain that lasts longer than 12 weeks. Drugs used to treat CP include analgesics such as opioids and nonsteroidal anti-inflammatory drug. Because of the low bioavailability of most drugs and/or the short half-life, the drugs in conventional treatment are not sufficient to treat CP. The development of new more effective therapeutic treatments for CP relief is essential for enhancing the patient quality of life and safety and avoiding or limiting risks of abuse, addiction or serious injuries posed by some of the present CP therapies. With this aim, several advanced Nanocarrier systems (NCSs) have been developed to increase bioavailability, therapeutic efficacy and safety. NCSs can be used effectively as a drug delivery system (DDS) with unique physicochemical-biological properties. The use of NCSs in the treatment of CP is one of the most popular research topics. For example, nanotechnology-based DDSs prepared with Eudragit&PLGA polymer of dexketoprofen trometamol that has a short-live, have entered the literature. Also, NCSs were prepared by using different polymers with flurbiprofen and ketoprofen lysine. When the results of the studies are examined, they are compared with the following results. Release rates of drugs with short half-lives were increased in vitro and in vivo. They concluded that side effects due to fluctuations in drug blood levels and toxicity, effective treatment and good patient compliance and the need for multiple dose regimens were eliminated, especially in oral administration. Nanotechnological DDSs capable of long-term drug release are new, important and promising systems for the treatment of CP with short half-life and low bioavailability drugs.
Alp Yildiz
Yildirim Beyazit University, Turkey
Title: Effect of oxidized regenerated cellulose application on post-trombectomy bleeding and pain
Time : 14:00-14:30
Biography:
Alp Yildiz born in Kutahya in 1983,has completed medical degree on Gazi University School of Medicine, has completed her PhD as General Surgery Specialist at 2015. He is one of the leading surgeons on colorectal surgery of a tertiary care university hospital in capital city Ankara. He has published more than 20 papers in reputed journals and has been serving as colorectal surgeon in Yildirim Beyazit University, Yenimahalle Training and Research Hospital.
Abstract:
Yildirim Beyazit University Yenimahalle Training and Research Hospital Ankara/Turkey. The aim of this study was to evaluate the effect of oxidized regenerated cellulose application on postoperative bleeding and pain after trombectomy for external trombosed hemorrhoids. After excluding patients with hemorrhagic disorder, chronic disease, and perianal abscess, trombectomy performed. After cleaning the area an elliptical incision made in the roof of the hemorrhoid, taking care to avoid the anal sphincter muscle and the incision directed radially from the anal orifice. After the thrombosed hemorrhoid unroofed, clot has removed and in Group-1 the cavity packed with Oxidized regerated cellulose(Oxicel ® Betatech Medical, Istanbul/Turkey), in Group-2 electrocauterised for hemostasis. The bleeding time and Pain was evaluated every day for 3 days postoperatively, and 10th day after the procedure. Secondary bleeding was reported at any time. A total of 21 patients in Group-1 (13 males, 8 females) between the ages of 24 and 54 years (mean age 43.46 ± 4.98) , a total of 14 patients in Group-2 (9 males, 5 females) (mean age 41.16 ± 3.75) were included in the study. Mean bleeding time showed no statistically significant difference between groups(p>0.05) The average pain score was greater in Group 2 than in Group 1 on each postoperative day (p < 0.05). Secondary bleeding was observed in 2 patients from Group-2. Oxicel application decreased pain levels while effectively controlling bleeding incidence during operation and the postoperative period.
Aybala Yildiz
Yildirim Beyazit University, Turkey
Title: Combination of irritable bowel syndrome with fibromyalgia and the effect of irritable bowel syndrome treatment on both
Time : 14:30-15:00
Biography:
Aybala Yildiz born in Ankara in 1981,has completed medical degree on Ankara University School of Medicine, has completed her PhD as General Surgery Specialist at 2010 and took the academical degree of associate professor at the age of 34. She is the leading surgeon of a tertiary care university hospital in capital city Ankara. She has published more than 30 papers in reputed journals and has been serving as a hospital board member of repute.
Abstract:
Few data are available to evaluate health-related quality of life of people with irritable bowel syndrome(IBS) and fewer data are available for anxiety and depression status in this patients. patients with IBS included the study. All patients has given 40 mg otilonium bromide-80 mg simeticone combination drug (Simflat®(Abdi Ä°brahim Pharmaceuticals, Ä°stanbul/Turkey)) in one tablet 3 times a day on meal time. Qol questionnaire(QoL), beck anxiety index (BAI), Hamilton depression index (HDI) and Fibromiyalgia symptom severity index(FMSS) applied before the treatment and after the treatment on follow-up at 3rd month. After the treatment BAI and HDI showed statistically significant improvement (p< 0.05) for all groups. BAI 6.98/3.11 and HDI 9.28/1.36 before and after treatment. Qol improved 48.87 to 77.77 (p< 0.05) and FMSS decreased 4.11 from 7.98 after treatment (p< 0.05). 64 patients of 114 showed complete recovery for both ibs and fibromyalgia after treatment (%56.14). In
the symptomatic treatment of Irritable Bowel Disease co-excistent with fibromyalgia, a major treatment alternative since being scientifically proven for their effectiveness for many years, Otilonium Bromide and Simethicone. On the other hand, when evaluated in respect to biotechnologic window ,this combination product with its unique approach as distinct from other drugs, has brought patient compliance into the forefront in chronic gas and dyspepsy affiliated with IBS which has problematic diagnose and treatment issues. This is why, it has been brought two different molecules which are used widespread but separately into a single tablet formulation: Otilonium Bromide with its spasmolytic, pain transmission reducing and antisecretory effects and Simethicone with its reducing effects on pain caused by excessive gas. Otilonium Bromide, which is in solid form and Simethicone which is in liquid form, are combined with the bilayer tablet technology by and presented to physicians in a single tablet as an innovative product. In the symptomatic treatment of Irritable Bowel Disease, a major treatment alternative since being scientifically proven for their effectiveness for many years, Otilonium Bromide and Simethicone's single tablet feature improves patient compliance of IBS patients and leads to improve the quality of life of IBS patients.
Sumithra Mohan
SRM College of Pharmacy, India
Title: Novel targets to neurological disorder - Alzheimer’s disease
Time : 15:00-15:30
Biography:
M. Sumithra , currently working as Associate Professor in SRM College of Pharmacy, SRMIST and has totally 12 years of teaching experience. Her Ph.D work focused on neuropharmacology with her specialization in Pharmacology. She has exposure on Alzheimer's disease, cancer studies and also perusing toxicological studies for formulations and phytomolecules. To her credit, she has presented papers in national and international conference and awarded Prize in AICTE sponsored National seminar and also awarded cash prize for PG research work. She has published 27 research and review articles in reputed National and
International Journals. She has guided 10 UG projects and 8 PG projects.
Abstract:
Neuropharmacology is a scientific study focused on the action of drugs used for psychiatric and neurodegenerative diseases. Neurological diseases occurs due to imbalance in molecular mechanism due to electrical and chemical signaling
disturbance. The primary focus on neuro pharmacological research is to develop novel targets to treat neurological disorders like schizophrenia, Parkinson's disease, epilepsy and hungintons disease. The prevalence of this disease varies from different regions of the country with a mean of 2394 per 1000000 population provided with rough estimation of 30 million people worldwide. Among the diseases, Alzheimer's and Parkinson's disease remains as great challenge in drug discovery. Alzheimer's disease is a neurodegenerative age related disease affecting the memory and disturbs visuospatial skills. Its hallmark includes hyper phosphorylation, glial activation, neurofibrillary tangles and amyloid plaques. Nowadays low educational status, occupational stress and inflammation leads to dementia and finally results in Alzheimer’s disease. On the other hand, genetic predisposition, long period uncontrolled cardiovascular disease, diabetes mellitus and dyslipidemia also promotes amyloid precursor protein formation resulting in Alzheimer's. Currently available drugs used for symptomatic relief but the etiology not cured. Novel approaches targeted to cure the etiology. Also the US FDA has approved few category of drugs which prevents beta-amyloid plaques and also hyper phosphorylation of proteins. The aim of this presentation is to highlight the current targets of this diseases and expected outcomes.
Break: Networking and Refreshment @ 15:30-16:00
Aseel Mahmoud
Liverpool John Moores University, UK
Title: Qualitative study of stakeholder’s perspectives on the current management and control of asthma patients in the North West of England
Time : 16:00-16:30
Biography:
Aseel Mahmoud has completed her Master degree in phrmaceutical sciences from Jordan University in Amman at 2013. In 2013 she joined Jordan University and worked as a part time teaching assisstant in the faculty of pharmacy. Then she joined Isra University in 2016. She holed a free lecturer position teaching pharmacy practice in the School of Pharmacy. Currently she is completing her PhD study in pharmacy practice in Liverpool John Moores University in the UK. Aseel is interested in research related to asthma services, pharmacy practice and multidisciplinary work.
Abstract:
Asthma is considered a public health problem, with an estimated 235 million people currently living with asthma globally, according to the World Health Organisation(1). However, there is a lack of evidence to inform the best way to organise structured asthma care in practice (2). In order to improve asthma management and control, the current levels of asthma control and management need to be evaluated in order to determine enablers for change. This study involved a total of 17 semistructured, face-to-face or telephone interviews with stakeholders including, for example: pharmacists and asthma consultant. Interview transcripts were analysed by thematic analysis. Seven key themes relating to asthma control and management were identified. Overall, participants felt that many adult asthma patients within their health care settings are poorly controlled and for several reasons including: poor inhaler technique, overtreatment and under treatment, poor medicine adherence – especially with preventer inhalers –, patient education and the current diagnosis pathway. The participants suggested that adult asthma patient treatment outcomes could be improved by providing better patient education, involving the patients in their treatment plan and improving the monitoring and diagnosis of asthma patients through multidisciplinary work. Interviewees felt that there were opportunities to utilise community pharmacy resources to improve asthma management and control by targeting certain adult asthma patient groups. The participants suggested many asthma patient groups, including for example: controlled asthma patients and young adult asthma patients. Further research will be performed to characterise asthma patient groups that could be targeted by community pharmacy and to develop a new care model for asthma patients.